Again, we observed a delayed tumor growth of GNE-KO tumors compared to wild-type tumors and an increased rejection rate of GNE-KO tumors treated with anti–PD-1 antibodies compared to wild-type tumors (50% versus 33%; fig. Here, PDCD1 is linked to neoplasm.